SKLB163

SKLB163 is a small molecule antitumor agent developed by the Collaborative Innovation Center of Biotherapy (State Key Laboratory of Biotherapy) at Sichuan University. It is characterized as a multi-target inhibitor, primarily acting as a tubulin polymerization inhibitor by binding to the colchicine-binding site, which leads to G2/M phase cell cycle arrest and apoptosis. Additionally, research and patents associated with the compound indicate its role as an inhibitor of the MDM2-p53 protein-protein interaction, a mechanism that restores the activity of the p53 tumor suppressor protein. SKLB163 has demonstrated potent in vitro and in vivo efficacy against various cancer types, including those with multi-drug resistance, and is currently in the preclinical pipeline for cancer therapy.